Bayesian Capital Management’s Novo Nordisk NVO Stock Holding History

Bayesian Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$407K	Sell	8,500 -20,100	-70%	-$864K	0.26%	109
2026 Q1	$1.05M	Buy	+28,600	New	+$1.36M	1.28%	19
2025 Q4	–	Sell	-68,300	Closed	-$3.79M	–	400
2025 Q3	$3.79M	Buy	68,300 +61,400	+890%	+$3.59M	0.77%	16
2025 Q2	$476K	Sell	6,900 -5,500	-44%	-$374K	0.08%	294
2025 Q1	$861K	Sell	12,400 -12,500	-50%	-$1.03M	0.14%	200
2024 Q4	$2.14M	Buy	+24,900	New	+$2.69M	0.26%	112
2024 Q1	–	Sell	-3,630	Closed	-$376K	–	1013
2023 Q4	$376K	Buy	+3,630	New	+$359K	0.04%	449
2023 Q1	–	Sell	-38,716	Closed	-$2.62M	–	1003
2022 Q4	$2.62M	Buy	38,716 +24,800	+178%	+$1.45M	0.38%	37
2022 Q3	$693K	Buy	13,916 +8,400	+152%	+$450K	0.14%	201
2022 Q2	$307K	Buy	5,516 +1,116	+25%	+$61.9K	0.06%	475
2022 Q1	$244K	Buy	+4,400	New	+$226K	0.04%	593
2021 Q4	–	Sell	-6,854	Closed	-$329K	–	478
2021 Q3	$329K	Buy	+6,854	New	+$331K	0.1%	248
2017 Q4	–	Sell	-83,676	Closed	-$2.01M	–	669
2017 Q3	$2.01M	Buy	83,676 +12,200	+17%	+$276K	0.48%	47
2017 Q2	$1.53M	Buy	+71,476	New	+$1.44M	0.57%	34

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bayesian Capital Management's NVO Position: Q2 2026 in Review

Bayesian Capital Management reduced its Novo Nordisk (NVO) stake by 70% in Q2 2026, selling an estimated $864K and leaving 8,500 shares worth $407K. The position accounts for 0.26% of the portfolio, ranked #109.

Bayesian Capital Management first reported a position in NVO in Q2 2017 and has held it in 14 quarters since. The position peaked at $3.79M in Q3 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Bayesian Capital Management held 8,500 shares of Novo Nordisk worth $407K as of Q2 2026.
Bayesian Capital Management sold 20,100 Novo Nordisk shares in Q2 2026, an estimated $864K.
Novo Nordisk made up 0.26% of Bayesian Capital Management's portfolio in Q2 2026, its #109 holding.
Bayesian Capital Management first reported a position in Novo Nordisk in Q2 2017 and has held it in 14 quarters since.
Bayesian Capital Management's Novo Nordisk position peaked at $3.79M in Q3 2025.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.